Ventyx Biosciences' VTX3232 Fails to Meet Weight Loss Expectations in Phase 2 Trial

Ventyx Biosciences' Phase 2 study results showed that VTX3232 did not meet the primary endpoint for reducing body weight in obese patients. The company's shares declined 65% in after-hours trading. While the study's outcome is disappointing, it is essential to note that the study was not powered to assess efficacy or safety, and additional studies are needed to determine the compound's potential in the treatment of obesity.